MedTrace Logo

Effect and Safety of Propofol Fumarate for Mother-to-child Blocking of Hepatitis B

NCT04135235 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 440

Last updated 2019-10-22

No results posted yet for this study

Summary

This study is a prospective study. The subject will select 440 cases of pregnant women with high hepatitis B virus load, and one group will take maternal and child blockade treatment with propofol fumarate. One group will take tenofovir disoproxil fumarate. Broken treatment, compare the failure rate of maternal and child blockade and the incidence of maternal and child adverse events in the two groups, and explore the efficacy and safety of propofol flavuril for the treatment of hepatitis B mother-infant block.

Conditions

  • Chronic Hepatitis B Infection
  • High Viral Load

Interventions

DRUG

TAF

Propofol tenofovir fumarate

DRUG

TDF

Dipirofurate fumarate tenofovir

Sponsors & Collaborators

  • Beijing Ditan Hospital

    lead OTHER

Principal Investigators

  • Wei Yi, Doctor · Beijing Ditan Hospital

  • Yao Xie, Doctor · Beijing Ditan Hospital

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-01
Primary Completion
2021-08-01
Completion
2021-08-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04135235 on ClinicalTrials.gov